{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:10:44Z","timestamp":1793398244564,"version":"4.5.0"},"reference-count":31,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>B-cell maturation antigen (BCMA)\u2013 and G protein\u2013coupled receptor class C group 5 member D (GPRC5D)\u2013directed therapies have shown high efficacy in the treatment of relapsed or refractory multiple myeloma, with multiple new immune therapies now approved. Preclinical studies have shown that the expression of BCMA and GPRC5D is heterogeneous in malignant plasma cells. We conducted a phase 1 dose-escalation trial of the BCMA chimeric antigen receptor (CAR) T-cell therapy MCARH125 alone or in combination with the GPRC5D CAR T-cell therapy MCARH109 in patients with relapsed or refractory multiple myeloma. Patients were treated across 3 dose levels, with the primary objective of establishing the safety of concurrent infusion. We treated 15 patients across 3 dose levels, including 6 patients who received MCARH125 alone and 9 patients treated with the concurrent infusion of MCARH125 and MCARH109. One patient each with MCARH 125 alone and the coinfusion of MCARH125 and MCARH109 developed immune effector cell\u2013associated hemophagocytic syndrome. There were no instances of grade \u22653 cytokine release syndrome or immune effector cell\u2013associated neurologic syndrome. The overall response for coinfusion was 78%, with a median progression-free survival of 18.2 months. Correlative analysis suggests that antigen loss may be an important mechanism of resistance even with dual-antigen targeting, and we show, to our knowledge for the first time that expansion of 1 CAR population may limit expansion of the second population because patients treated with dual CARs had significantly less BCMA CAR expansion compared with patients treated with BCMA CAR alone, despite equivalent BCMA CAR T-cell doses at infusion. This trial was registered at www.clinicaltrials.gov as NCT05431608.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025032122","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:57:02Z","timestamp":1783450622000},"page":"2121-2131","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Concurrent administration of BCMA and GPRC5D CAR T cells for advanced multiple myeloma"],"prefix":"10.1182","volume":"148","author":[{"given":"Sham","family":"Mailankody","sequence":"first","affiliation":[{"name":"1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Cell Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"3Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7718-8721","authenticated-orcid":false,"given":"Sneha","family":"Mitra","sequence":"additional","affiliation":[{"name":"4Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Herrera","sequence":"additional","affiliation":[{"name":"2Cell Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bachisio","family":"Ziccheddu","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briana","family":"Cadzin","sequence":"additional","affiliation":[{"name":"2Cell Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9889-2702","authenticated-orcid":false,"given":"Ozgur Can","family":"Eren","sequence":"additional","affiliation":[{"name":"5Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasmin","family":"Farzana","sequence":"additional","affiliation":[{"name":"2Cell Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahmin","family":"Ullah","sequence":"additional","affiliation":[{"name":"2Cell Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Landa","sequence":"additional","affiliation":[{"name":"6Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2178-8493","authenticated-orcid":false,"given":"Andriy","family":"Derkach","sequence":"additional","affiliation":[{"name":"7Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagrutiben","family":"Chaudhari","sequence":"additional","affiliation":[{"name":"8Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"9Cancer Cell Therapy Initiative, Herbert Irving Comprehensive Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7807-6775","authenticated-orcid":false,"given":"Devin P.","family":"McAvoy","sequence":"additional","affiliation":[{"name":"10Immune Discovery and Modeling Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1190-1491","authenticated-orcid":false,"given":"Kinga","family":"Hosszu","sequence":"additional","affiliation":[{"name":"10Immune Discovery and Modeling Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-0456","authenticated-orcid":false,"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[{"name":"2Cell Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"11Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3152-1189","authenticated-orcid":false,"given":"Heather","family":"Landau","sequence":"additional","affiliation":[{"name":"2Cell Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"11Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-1620","authenticated-orcid":false,"given":"Francesco","family":"Maura","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-5256","authenticated-orcid":false,"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[{"name":"5Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-5053","authenticated-orcid":false,"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[{"name":"2Cell Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"11Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyan","family":"Wang","sequence":"additional","affiliation":[{"name":"8Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9031-8025","authenticated-orcid":false,"given":"Michel","family":"Sadelain","sequence":"additional","affiliation":[{"name":"9Cancer Cell Therapy Initiative, Herbert Irving Comprehensive Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Smith","sequence":"additional","affiliation":[{"name":"12Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renier J.","family":"Brentjens","sequence":"additional","affiliation":[{"name":"13Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4571-5910","authenticated-orcid":false,"given":"Christina","family":"Leslie","sequence":"additional","affiliation":[{"name":"4Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Cell Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"3Department of Medicine, Weill Cornell Medical College, New York, NY"},{"name":"11Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3595-7596","authenticated-orcid":false,"given":"Karlo","family":"Perica","sequence":"additional","affiliation":[{"name":"2Cell Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2026102211215277600_bib1","unstructured":"SEER Cancer Stat Facts: Myeloma. National Cancer Institute. Accessed 13 July 2026. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"2026102211215277600_bib2","doi-asserted-by":"crossref","first-page":"m3176","DOI":"10.1136\/bmj.m3176","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Shah","year":"2020","journal-title":"BMJ"},{"key":"2026102211215277600_bib3","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1182\/hematology.2023000434","article-title":"Current use of CAR T cells to treat multiple myeloma","volume":"2023(1)","author":"Firestone","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"2026102211215277600_bib4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1182\/hematology.2023000433","article-title":"Current use of bispecific antibodies to treat multiple myeloma","volume":"2023","author":"Lee","year":"2023","journal-title":"Hematology"},{"issue":"8","key":"2026102211215277600_bib5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"2026102211215277600_bib6","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"10297","key":"2026102211215277600_bib7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"2026102211215277600_bib8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"2026102211215277600_bib9","first-page":"1722","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"2026102211215277600_bib10","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"12","key":"2026102211215277600_bib11","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.clml.2025.06.014","article-title":"Indirect comparison of linvoseltamab versus teclistamab for the treatment of triple-class exposed relapsed\/refractory multiple myeloma","volume":"25","author":"Lee","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"2026102211215277600_bib12","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"13","key":"2026102211215277600_bib13","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"2026102211215277600_bib14","doi-asserted-by":"crossref","first-page":"E107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CART cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"},{"issue":"14","key":"2026102211215277600_bib15","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1200\/JCO.22.01824","article-title":"Anti-G protein-coupled receptor, class c group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase II trial","volume":"41","author":"Xia","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026102211215277600_bib32","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1182\/blood.2025030750","article-title":"Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed\/refractory multiple myeloma","volume":"148","author":"Bal","year":"2026","journal-title":"Blood"},{"issue":"485","key":"2026102211215277600_bib16","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"issue":"15","key":"2026102211215277600_bib17","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood.2019003342","article-title":"A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"issue":"2","key":"2026102211215277600_bib18","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma","volume":"1","author":"Fern\u00e1ndez de Larrea","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"suppl 1","key":"2026102211215277600_bib19","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2023-174941","article-title":"Characterization of JNJ-79635322, a novel BCMAxGPRC5DxCD3 T-cell redirecting trispecific antibody, for the treatment of multiple myeloma [abstract]","volume":"142","author":"Pillarisetti","year":"2023","journal-title":"Blood"},{"issue":"suppl 15","key":"2026102211215277600_bib20","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","article-title":"Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): update of the phase 1\/2 EVOLVE study (NCT03430011)","volume":"38","author":"Mailankody","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026102211215277600_bib31","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"2026102211215277600_bib21","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJMc2308544","article-title":"Genetic basis of relapse after GPRC5D-targeted CAR T cells","volume":"389","author":"Mi","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"2026102211215277600_bib22","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO-24-01785","article-title":"Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: an updated analysis","volume":"43","author":"Jurgens","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026102211215277600_bib23","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"19","key":"2026102211215277600_bib24","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"issue":"9","key":"2026102211215277600_bib25","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/s43018-024-00763-8","article-title":"Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma","volume":"5","author":"Rade","year":"2024","journal-title":"Nat Cancer"},{"issue":"10","key":"2026102211215277600_bib26","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s41587-021-00927-2","article-title":"Scalable, multimodal profiling of chromatin accessibility, gene expression and protein levels in single cells","volume":"39","author":"Mimitou","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"4","key":"2026102211215277600_bib28","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","article-title":"Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating","volume":"13","author":"Hamieh","year":"2023","journal-title":"Cancer Discov"},{"issue":"10","key":"2026102211215277600_bib29","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1016\/S2352-3026(24)00176-5","article-title":"Anti-BCMA\/GPRC5D bispecific CART cells in patients with relapsed or refractory multiple myeloma: a single-arm single-centre, phase 1 trial","volume":"11","author":"Zhou","year":"2024","journal-title":"Lancet Haematol"},{"issue":"2","key":"2026102211215277600_bib30","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus teclistamab in relapsed or refractory multiple myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/17\/2121\/2595425\/blood_bld-2025-032122-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/17\/2121\/2595425\/blood_bld-2025-032122-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:22:00Z","timestamp":1792682520000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/17\/2121\/569578\/Concurrent-administration-of-BCMA-and-GPRC5D-CAR-T"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":31,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026,10,22]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025032122","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,22]]},"published":{"date-parts":[[2026,10,22]]}}}